Characteristics of ML00253764 Rescuing the MC4R Deficient Mutants

doi:10.13560/j.cnki.biotech.bull.1985.2016.05.034

Abstract

Abstract: To determine the specificity and internalization kinetics of non-peptide small molecule ML00253764 rescuing the obesity-causing MC4R mutants，the cell model for the stable expression of melanocortin receptors and their mutants were established. The results by flow cytometry（FACS）showed that ML00253764 resulted in the increase of the membrane surface expression of MC4R deficient mutation receptor N62S and P78L by 43% and 34%，respectively，while almost no effects to other melanocortin receptor and their mutants，demonstrating this rescue mediated by ML00253764 was MC4R receptor- and mutant- specific. Further study showed that the internalization of rescued receptors was similar to the wild type（WT）receptor，and there was no significant difference in rate of internalization t1/2. Both endogenous ligands α-MSH and AgRP had no rescue effect on the membrane surface expression of MC4R deficient mutation receptor，proving that action way of ML00253764 was different from that of above two，and what mutant receptors were rescued resulted from the specificity of pharmacological chaperone with cell membrane permeability.

Key words: melanocortin-4 receptor, pharmacological chaperone, rescue

WANG Xiao-hua,CAO Xiao-hong,FAN Zhen-chuan. Characteristics of ML00253764 Rescuing the MC4R Deficient Mutants[J]. Biotechnology Bulletin, 2016, 32(5): 255-259.

References

[1]Duffy DL, Box NF, Chen W, et al. Interactive effects of MC1R and OCA2 on melanoma risk phenotypes[J]. Hum Mol Genet, 2004, 13（4）：447-461.
[2]Metherell LA, Chapple JP, Cooray S, et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2[J]. Nat Genet, 2005, 37（2）：166-170.
[3]Tao YX. Functional characterization of novel melanocortin-3 receptor mutations identified from obese subjects[J]. Biochim Biophys Acta, 2007, 1772（10）：1167-1174.
[4]Tao YX. The melanocortin-4 receptor：physiology pharmacology and pathophysiology[J]. Endocrine Reviews, 2010, 31（4）：506-543.
[5]Farooqi IS, Yeo GS, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency[J]. J Clin Invest, 2000, 106（2）：271-279.
[6]Hinney A, Schmidt A, Nottebom K, et al. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans[J]. Journal of Clinical Endocrinology and Metabolism, 1999, 84（4）：1483-1486.
[7]Chen W, Kelly MA, Opitz Araya X, et al. Exocrine gland dysfunction in MC5R-deficient mice：evidence for coordinated regulation of exocrine gland function by melanocortin peptides[J]. Cell, 1997, 91（6）：789-798.
[8]Bernier V, Lagace M, Lonergan M, et al. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059[J]. Molecular Endocrinology, 2004, 18（8）：2074-2084.
[9]Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus[J]. Journal of the American Society of Nephrology, 2006, 17（1）：232-243.
[10]Vos TJ, Caracoti A, Che JL, et al. Identification of 2-[2-[2-（5-bromo-2-methoxyphenyl）-ethyl]-4, 5-dihydro-1H-imidazole（ML00257364）, a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model[J]. J Med Chem, 2004, 47（7）：1602-1604.
[11]Fan ZC, Tao YX. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients[J]. J Cell Mol Med, 2009, 13（9B）：3268-3282.
[12]Wang XH, Wang HM, Zhao BL, et al. Rescue of defective MC4R cell-surface expression and signaling by a novel pharmacoperone Ipsen 17[J]. J Mol Endocrinol, 2014, 53（1）：1-13.
[13]Conn PM, Ulloa Aguirre A, Janovick JA. G protein-coupled receptor trafficking in health and disease：lessons learned to prepare for therapeutic mutant rescue in vivo[J]. Pharmacol Rev, 2007, 59（3）：225-250.
[14]Meimaridou E, Gooljar SB, Ramnarace N, et al. The Cytosolic chaperone Hsc70 promotes traffic to the cell surface of intracellular retained melanocortin-4 receptor mutants[J]. Molecular Endocrinology, 2011, 25（9）：1650-1660.
[15]Conn PM, Ulloa-Aguirre A. Trafficking of G-protein-coupled receptors to the plasma membrane：insights for pharmacoperone drugs[J]. Trends Endocrinol Met, 2010, 21（3）：190-197.
[16]Granell S, Serra-Juhé C, Martos-Moreno Gá, et al. A novel melanocortin-4 receptor mutation MC4R-P272L associated with severe obesity has increased propensity to be ubiquitinated in the ER in the face of correct folding[J]. PLoS One, 2012, 7（12）：e50894.
[17]Castro-Fernandez C, Maya-Nunez G, Conn PM. Beyond the signal sequence：protein routing in health and disease[J]. Endocr Rev, 2005, 26（4）：479-503.
[18]Breit A, Wolff K, Kalwa H, et al. The natural inverse agonist agouti-related protein induces arrestin-mediated endocytosis of melanocortin-3 and -4 receptors[J]. J Biol Chem, 2006, 281（49）：37447-37456.